好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Successful Prevention of Bow Hunter's Stroke Associated with Rheumatoid Atlantoaxial Subluxation via Coil Occlusion
Cerebrovascular Disease and Interventional Neurology
P8 - Poster Session 8 (11:45 AM-12:45 PM)
6-027

To describe a case of recurrent posterior circulation stroke (PCS) associated with atlantoaxial subluxation (AAS) that was treated with coil occlusion. 

Recurrent PCS caused by rotational vertebral artery insufficiency is known as bow hunter's stroke (BHS). Rheumatoid arthritis (RA)-related AAS is a rare cause of BHS. Conservative or surgical treatment is usually provided to patients with AAS-associated BHS. However, there are no reports of the use of endovascular treatment for preventing stroke recurrence.

NA 

A 70-year-old woman with RA-associated AAS had recurrent acute ischemic PCS despite anti-thrombotic therapy. Repeated magnetic resonance imaging revealed disappearance and reappearance of the right vertebral artery (VA). Computed tomography angiography revealed that the right VA was situated near the dens; AAS was also noted. Chronic intimal damage with a rotational pattern due to mechanical compression of the right VA was suspected as the cause of repeated thrombosis, which resulted in artery-to-artery embolism. Digital subtraction angiography (DSA) of the right VA revealed disappearance of the right posterior inferior cerebellar artery (PICA) on anteflexion, while DSA of the left VA revealed that the distal portion of the right VA, including the PICA, was supplied via retrograde blood flow from the left VA. Therefore, coil occlusion was performed on the right VA proximal to the PICA origin. Thereafter, the patient has been stroke-free for over 18 months.

We believe this is the first reported case of successful prevention of recurrent AAS-associated BHS via coil occlusion of the VA. Surgical treatment does not rectify intravascular damage, which may cause stroke recurrence, and it can be challenging because of the high risk of complications in older patients with RA. The endovascular approach, including coil occlusion, might be a feasible option for managing AAS-associated BHS.

Authors/Disclosures
Ryoichi Inoue, MD (Kyoto University Hsospital)
PRESENTER
Dr. Inoue has nothing to disclose.
No disclosure on file
No disclosure on file
No disclosure on file
Ryosuke Takahashi, MD (Kyoto University Graduate School of Medicine) Dr. Takahashi has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Kan Institute. Dr. Takahashi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Takeda Pharma. Dr. Takahashi has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Ono Pharma. Dr. Takahashi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Kyowa Kirin Pharma. Dr. Takahashi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Otsuka Pharma. Dr. Takahashi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Abbvie. Dr. Takahashi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Eisai. Dr. Takahashi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Chugai Pharma. Dr. Takahashi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alexion. Dr. Takahashi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Argenix. Dr. Takahashi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alnyrum. Dr. Takahashi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sumitomo Pharma. The institution of Dr. Takahashi has received research support from MEXT. Japan. The institution of Dr. Takahashi has received research support from AMED, Japan. The institution of Dr. Takahashi has received research support from JST, Japan. The institution of Dr. Takahashi has received research support from MHLW, Japan. The institution of Dr. Takahashi has received research support from Sumitomo Pharma. The institution of Dr. Takahashi has received research support from Takeda Pharma. The institution of Dr. Takahashi has received research support from Otsuka Pharma. Dr. Takahashi has received personal compensation in the range of $500-$4,999 for serving as a PO with AMED, Japan. Dr. Takahashi has received personal compensation in the range of $500-$4,999 for serving as a PO with JST, Japan.